PMID- 28715780
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20211204
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 74
DP  - 2017 Sep
TI  - Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome.
PG  - 59-63
LID - S1525-5050(17)30200-7 [pii]
LID - 10.1016/j.yebeh.2017.05.036 [doi]
AB  - AIM: Report the use of perampanel treatment in children with Lennox-Gastaut 
      syndrome (LGS). METHOD: We conducted a prospective study of 13 LGS patients 
      (seven male; mean age, 12.8years) treated with adjunctive perampanel therapy. 
      Perampanel was initiated at 2mg/day and titrated to a median maximum dose of 
      6mg/day. RESULTS: After a mean follow-up duration of 10.8months (range, 
      1-24months), nine patients (69.2%) were responders (>/=50% reduction in total 
      seizure frequency) and nine (69.2%) were rated by their physician as "much 
      improved" or "very much improved". Four patients (30.8%) discontinued perampanel 
      due to the lack of efficacy (n=2) and seizure aggravation (n=2). No patients 
      discontinued due to other adverse events (AEs). AEs were reported for six 
      patients (46.2%) and comprised decreased activity/social interaction (n=3), 
      behavior disturbance with agitation (n=2), and/or fatigue (n=2). All AEs became 
      manageable after perampanel dosing was decreased. Improvements in cognitive 
      function and/or behavior were reported for seven patients (53.8%). Introduction 
      of perampanel allowed the dose reduction and/or discontinuation of other 
      treatments in seven patients (53.8%). INTERPRETATION: Perampanel was efficacious 
      and generally well tolerated as an adjunctive treatment for seizures associated 
      with LGS, supporting further research in this area.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Auvin, Stephane
AU  - Auvin S
AD  - Universite Paris Diderot, Sorbonne Paris Cite, INSERM UMR1141, 75019 Paris, 
      France; AP-HP, Hopital Robert Debre, Service de Neurologie Pediatrique et des 
      Maladies Metaboliques, 75019 Paris, France. Electronic address: 
      stephane.auvin@inserm.fr.
FAU - Dozieres, Blandine
AU  - Dozieres B
AD  - AP-HP, Hopital Robert Debre, Service de Neurologie Pediatrique et des Maladies 
      Metaboliques, 75019 Paris, France.
FAU - Ilea, Adina
AU  - Ilea A
AD  - AP-HP, Hopital Robert Debre, Service de Neurologie Pediatrique et des Maladies 
      Metaboliques, 75019 Paris, France.
FAU - Delanoe, Catherine
AU  - Delanoe C
AD  - AP-HP, Hopital Robert Debre, Service des Explorations Fonctionnelles, 75019 
      Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Adolescent
MH  - Anticonvulsants/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lennox Gastaut Syndrome/*diagnosis/*drug therapy/epidemiology
MH  - Male
MH  - Nitriles
MH  - Prospective Studies
MH  - Pyridones/*therapeutic use
MH  - Seizures/diagnosis/drug therapy/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AMPA receptor antagonist
OT  - Antiepileptic drug
OT  - Epilepsy
OT  - Epileptic encephalopathy
OT  - Lennox-Gastaut syndrome
EDAT- 2017/07/18 06:00
MHDA- 2018/04/04 06:00
CRDT- 2017/07/18 06:00
PHST- 2017/03/12 00:00 [received]
PHST- 2017/05/23 00:00 [revised]
PHST- 2017/05/27 00:00 [accepted]
PHST- 2017/07/18 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/07/18 06:00 [entrez]
AID - S1525-5050(17)30200-7 [pii]
AID - 10.1016/j.yebeh.2017.05.036 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2017 Sep;74:59-63. doi: 10.1016/j.yebeh.2017.05.036. Epub 2017 
      Jul 14.